

Explanation of Responses:

Remarks:

(1) Effective April 30, 2015, the Board of Directors of DanDrit Biotech USAS, Inc. appointed Lone Degn to serve in the office of Chief Financial Officer until her successor is duly elected, qualified and seated or until her earlier resignation or removal.

No securities are beneficially owned.

/s/ Lone Degn 05/26/2015

** Signature of Date
Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.